MicroRNA as an Early Biomarker of Neonatal Sepsis

JOUZA, Martin, Júlia BOHOŠOVÁ, Andrea STANÍKOVÁ, Jakub PECL, Ondřej SLABÝ and Petr JABANDŽIEV. MicroRNA as an Early Biomarker of Neonatal Sepsis. FRONTIERS IN PEDIATRICS. SWITZERLAND: FRONTIERS MEDIA SA, 2022, vol. 10, May 2022, p. 1-8. ISSN 2296-2360. Available from: https://dx.doi.org/10.3389/fped.2022.854324.

Basic information

• Original name: MicroRNA as an Early Biomarker of Neonatal Sepsis
• Authors: JOUZA, Martin (203 Czech Republic, belonging to the institution), Júlia BOHOŠOVÁ (703 Slovakia, belonging to the institution), Andrea STANÍKOVÁ (703 Slovakia, belonging to the institution), Jakub PECL (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution) and Petr JABANDŽIEV (203 Czech Republic, guarantor, belonging to the institution).
• Edition: FRONTIERS IN PEDIATRICS, SWITZERLAND, FRONTIERS MEDIA SA, 2022, 2296-2360.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30209 Paediatrics
• Country of publisher: Switzerland
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 2.600
• RIV identification code: RIV/00216224:14110/22:00126832
• Organization unit: Faculty of Medicine
• Doi: http://dx.doi.org/10.3389/fped.2022.854324
• UT WoS: 000802241600001
• Keywords in English: miRNA; inflammation; CRP; IL-6; sepsis
• Tags: 14110317, 14110513, podil, rivok
• Tags: International impact, Reviewed

Abstract

Sepsis is a major cause of lethality in neonatal intensive care units. Despite significant advances in neonatal care and growing scientific knowledge about the disease, 4 of every 10 infants born in developed countries and suffering from sepsis die or experience considerable disability, including substantial and permanent neurodevelopmental impairment. Pharmacological treatment strategies for neonatal sepsis remain limited and mainly based upon early initiation of antibiotics and supportive treatment. In this context, numerous clinical and serum-based markers have been evaluated for diagnosing sepsis and evaluating its severity and etiology. MicroRNAs (miRNAs) do not encode for proteins but regulate gene expression by inhibiting the translation or transcription of their target mRNAs. Recently, it was demonstrated in adult patients that miRNAs are released into the circulation and that the spectrum of circulating miRNAs is altered during various pathologic conditions, such as inflammation, infection, and sepsis. Here, we summarize current findings on the role of circulating miRNAs in the diagnosis and staging of neonatal sepsis. The conclusions point to substantial diagnostic potential, and several miRNAs have been validated independently by different teams, namely miR-16a, miR-16, miR-96-5p, miR-141, miR-181a, and miR-1184.